155 related articles for article (PubMed ID: 17323113)
1. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.
Arnold A; Payne S; Fisher S; Fricker D; Soloway J; White SM; Novelli M; MacDonald K; Mackay J; Groves R; Canham N
Fam Cancer; 2007; 6(3):317-21. PubMed ID: 17323113
[TBL] [Abstract][Full Text] [Related]
2. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
3. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
4. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
5. Multiple benign adnexal tumours: Anything but benign.
McCarthy RL; Thomas CL; Isaacs F
Australas J Dermatol; 2019 Aug; 60(3):234-236. PubMed ID: 30671930
[TBL] [Abstract][Full Text] [Related]
6. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
7. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
8. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms.
Schwartz RA; Goldberg DJ; Mahmood F; DeJager RL; Lambert WC; Najem AZ; Cohen PJ
Dermatologica; 1989; 178(1):23-8. PubMed ID: 2917677
[TBL] [Abstract][Full Text] [Related]
9. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
10. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
11. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
12. [Sebaceous tumors and Muir-Torre syndrome].
Bourlond F; Cribier B; Lipsker D; Velter C
Ann Dermatol Venereol; 2015; 142(6-7):456-9. PubMed ID: 25890836
[No Abstract] [Full Text] [Related]
13. Muir-Torre syndrome.
Navi D; Wadhera A; Fung MA; Fazel N
Dermatol Online J; 2006 Sep; 12(5):4. PubMed ID: 16962019
[TBL] [Abstract][Full Text] [Related]
14. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre syndrome: clinical features and molecular genetic analysis.
Esche C; Kruse R; Lamberti C; Friedl W; Propping P; Lehmann P; Ruzicka T
Br J Dermatol; 1997 Jun; 136(6):913-7. PubMed ID: 9217825
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
17. The Muir-Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies.
Warschaw KE; Eble JN; Hood AF; Wolverton SE; Halling KC
J Cutan Pathol; 1997 Sep; 24(8):511-8. PubMed ID: 9331898
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
20. Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness.
Tischkowitz M; Gologan A; Srolovitz H; Khanna M; Foulkes WD
Br J Cancer; 2006 Jul; 95(2):243-4. PubMed ID: 16786041
[No Abstract] [Full Text] [Related]
[Next] [New Search]
